Grafalon

Grafalon is a rabbit-derived anti‑T lymphocyte immunoglobulin for human use, supplied as an intravenous preparation. The product contains the active ingredient Anti‑T Lymphocyte Immunoglobulin (Rabbit) and is marketed in the European Union. Strength and specific dosage form are not disclosed in the public summary. Grafalon is classified as an immunosuppressant and is available only by prescription. It is used primarily in transplant and autoimmune contexts under medical supervision.

Grafalon is employed in clinical settings where modulation of the immune response is required.

- Prevention of acute rejection in organ transplantation, including kidney, liver, and heart grafts. - Treatment of severe aplastic anemia when conventional therapies have failed. - Management of graft‑versus‑host disease (GVHD) after hematopoietic stem cell transplantation. - Induction of immunosuppression in selected autoimmune disorders that are refractory to standard treatment.

The immunologic activity of Grafalon can be associated with a range of adverse effects, varying in frequency and severity.

Common: - Fever, chills, or rigors during or shortly after infusion. - Infusion‑related reactions such as flushing, rash, or mild hypotension. - Transient leukopenia or lymphopenia. - Mild hypertension or tachycardia. - Nausea or mild gastrointestinal discomfort.

Serious: - Severe infections, including opportunistic bacterial, viral, or fungal pathogens. - Cytokine release syndrome presenting with high fever, hypotension, and respiratory distress. - Serum sickness‑like reactions with fever, arthralgia, and rash. - Acute renal impairment or hemolytic anemia. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.

Clinicians should consider several safety aspects before initiating Grafalon therapy.

- Assess baseline complete blood count and renal function; monitor these parameters regularly during treatment. - Screen for active infections, including hepatitis B, C, HIV, and tuberculosis, and treat appropriately before use. - Use caution in patients with a history of hypersensitivity to rabbit proteins or other immunoglobulin products. - Evaluate cardiovascular status, as infusion may provoke hemodynamic changes. - Counsel patients about the increased risk of malignancies associated with long‑term immunosuppression. - Avoid use during pregnancy or lactation unless the potential benefit justifies the potential risk.

Grafalon may interact with other agents that influence immune function or hemodynamics.

Avoid: - Concurrent use of other potent immunosuppressants (e.g., anti‑thymocyte globulin, alemtuzumab) without careful monitoring. - Live vaccines during and for several weeks after therapy due to impaired immune response. - High‑dose corticosteroids combined without dose adjustment, which may exacerbate infection risk.

Use with caution: - Antimicrobial prophylaxis agents (e.g., trimethoprim‑sulfamethoxazole) to prevent opportunistic infections. - Anticoagulants, as Grafalon‑related thrombocytopenia may increase bleeding risk. - Drugs that affect renal clearance (e.g., aminoglycosides) in patients with pre‑existing kidney dysfunction.